BSH 2017 | How the treatment of AML will change
Mary Frances McMullin
Mary Frances McMullin, MD of Belfast City Hospital, Belfast, UK discusses targeted therapy and immunotherapy for acute myeloid leukemia (AML) held at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Prof. McMullin explains that she was part of a discussion at BSH on targeted therapy and immunotherapy for AML. We are in the era of molecular medicine as our understanding of mutations underlying disease is improving and she explains that this may change the treatment of AML.
Related videos
2:11
Regulatory approval of CPX-351 for secondary AML
Charles Craddock
et al.
2:05
UK NCRI AML17 trial update: everolimus addition for consolidation
Robert Hills
1:22
Update on CAR T-cell therapy at the City of Hope
Steven Rosen
4:31
Limitations of targeted therapy for AML
Harry Erba
4:42
Gene-based treatments show positive outcomes in AML
Harry Erba
